The drug candidate, a single peptide with agonist activity at the glucose-dependent insulinotropic polypeptide (GIP), GLP-1 and glucagon receptors, was associated with significant weight loss, improved glycemic control and cardiovascular health
Dizziness during GLP-1 agonist use is frequently a dehydration symptom rather than a direct drug effect, and correcting hydration often resolves it
This includes the release of pro-inflammatory cytokines like IL-6 and TNF-alpha, which can cross the blood-brain barrier and cause severe neuroinflammation
Usually hypokalemia is caused by factors other than not eating enough food rich in potassium, such as complications due to kidney function, diuretic use, or being very sick and losing fluids
Biggest plus: Published clinical research backing their treatment approach rare for any telehealth provider
Does Wegovy, Mounjaro, or Ozempic cause hair loss